companies reata-pharmaceuticals-inc 
Benzinga
JULY 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB ) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA ) for $172.50 The analysts say the asset and other pipeline Nrf2 activators fit well within the company's rare neurology franchise. per share in cash, reflecting an enterprise value of approximately $7.3
Benzinga
SEPTEMBER 26, 2023
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich's ataxia in the U.S. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. NASDAQ: BIIB ) – has completed the acquisition of Reata Pharmaceuticals, Inc.
Benzinga
JULY 28, 2023
and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. NASDAQ: BIIB ) and Reata Pharmaceuticals, Inc. NASDAQ: RETA ) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 CAMBRIDGE, Mass.
Expert insights. Personalized for you.
52 
Let's personalize your content